ZMB Member Sebastian Bauer
ZMB Member
Sebastian Bauer
Next ZMB-Member
Prof. Dr. Sebastian Bauer
West German Cancer Center (WTZ)
University Hospital Essen
Hufelandstr. 55
45147 Essen
- +49 201 723 2112
- Website
- Selected Publications
- Publication Metrics
- ZMB Research Program
Oncology
Research Overview
- Analysis of oncogenetic signalling pathways in soft-tissue sarcoma (esp. GIST)
- Evaluation of purposive, small molecular inhibitors of tyrosine kinases in soft-tissue sarcoma
- Development of soft-tissue sarcoma models (cell lines and Xenografts)
- Evaluation of preclinical diagnostic techniques/methods (in vitro/in vivo) for GIST and other soft-tissue sarcoma
Selected Publications
-
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRAIn: Nature Communications Vol. 15 (2024) Nr. 1, 63Online Full Text: dx.doi.org/ (Open Access)
-
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors : A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesIn: Clinical Cancer Research Vol. 30 (2024) Nr. 4, pp. 719 - 728Online Full Text: dx.doi.org/
-
Correction to: Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationIn: Nature Communications Vol. 15 (2024) Nr. 1, 2364Online Full Text: dx.doi.org/ (Open Access)
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor : ctDNA biomarker analysis of the phase 3 INTRIGUE trialIn: Nature Medicine Vol. 30 (2024) Nr. 2, pp. 498 - 506Online Full Text: dx.doi.org/ (Open Access)
-
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized TrialIn: Clinical Cancer Research Vol. 29 (2023) Nr. 17, pp. 3313 - 3319Online Full Text: dx.doi.org/ (Open Access)
-
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationIn: Nature Communications Vol. 14 (2023) Nr. 1, pp. 4632Online Full Text: dx.doi.org/ (Open Access)
-
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 TrialIn: Clinical Cancer Research Vol. 29 (2023) Nr. 24, pp. 5057 - 5068Online Full Text: dx.doi.org/
-
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations : Results from a Multi-institutional European Retrospective StudyIn: Clinical Cancer Research Vol. 28 (2022) Nr. 8, pp. 1672 - 1679Online Full Text: dx.doi.org/ (Open Access)
-
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma : Results from a Proof-of-Concept, Phase Ib StudyIn: Clinical Cancer Research Vol. 28 (2022) Nr. 6, pp. 1087 - 1097Online Full Text: dx.doi.org/ (Open Access)
-
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaIn: Clinical Cancer Research Vol. 28 (2022) Nr. 5, pp. 870 - 881Online Full Text: dx.doi.org/ (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4346 - 4353Online Full Text: dx.doi.org/ (Open Access)
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS StudyIn: Clinical Cancer Research Vol. 27 (2021) Nr. 23, pp. 6333 - 6342Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Defective homologous recombination DNA repair as therapeutic target in advanced chordomaIn: Nature Communications Vol. 10 (2019) Nr. 1, pp. 1635Online Full Text: dx.doi.org/ (Open Access)
-
Integrative genomic and transcriptomic analysis of leiomyosarcomaIn: Nature Communications Vol. 9 (2018) Nr. 1, pp. 144Online Full Text: dx.doi.org/ (Open Access)
-
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationIn: Nature Communications Vol. 8 (2017) pp. 14674Online Full Text: dx.doi.org/ (Open Access)
-
Sustained mutant KIT activation in the Golgi complex is mediated by PKC-θ in gastrointestinal stromal tumorsIn: Clinical Cancer Research Vol. 23 (2017) Nr. 3, pp. 845 - 856Online Full Text: dx.doi.org/
-
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsIn: Clinical Cancer Research Vol. 20 (2014) Nr. 22, pp. 5745 - 5755Online Full Text: dx.doi.org/
-
Targeting glucose metabolism by 2-deoxyglucose in gastrointestinal stromal tumorsIn: Cancer Research Vol. 74 (2014) Nr. 19 Suppl.,Online Full Text: dx.doi.org/
-
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal TumorsIn: Cancer Research Vol. 73 (2013) Nr. 12, pp. 3661 - 3670Online Full Text: dx.doi.org/
-
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GISTIn: Cancer Research Vol. 73 (2013) Nr. Suppl. 8,Online Full Text: dx.doi.org/
-
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsIn: Cancer Research Vol. 70 (2010) Nr. 1, pp. 150 - 159Online Full Text: dx.doi.org/
-
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsIn: Cancer Research Vol. 69 (2009) Nr. 17, pp. 6941 - 6950Online Full Text: dx.doi.org/ (Open Access)